Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Citius Oncology, Inc.NASDAQ: CTOR
Deferred Revenue · Q2 FY2026 · quarter ended Mar 2026
Deferred revenue remains negative
Q2 FY2026 deferred revenue was $0, compared with $0 a year earlier.
Context
- Deferred revenue amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Deferred revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 0 | — |
| FY2024 | 2024-09-30 | 0 | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
Deferred Revenue vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 deferred revenue of $0 is the 4th highest of the 10 companies compared; the peer median is $0.
- Deferred revenue amounts to 0.0% of total assets for CTOR, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.01M | +51.2% | +58.8% | 4.5% | |
| Mar 2026 | $2.41M | +65.3% | — | 2.8% | |
| Mar 2026 | $582K | +174.5% | -79.2% | 0.2% | |
CTORCitius Oncology, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | -70.8% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding CTOR) | $0 | +51.2% | -70.8% | 0.0% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.